Please login to the form below

Not currently logged in
Email:
Password:

cancer immunotherapies

This page shows the latest cancer immunotherapies news and features for those working in and with pharma, biotech and healthcare.

NICE lung cancer backing for Keytruda is biggest expansion yet

NICE lung cancer backing for Keytruda is biggest expansion yet

cell lung cancer (NSCLC) patients in combination with chemotherapy for up to two years. ... The ruling confirms Keytruda's dominance among PD-1/PD-L1 immunotherapies in treating lung cancer in England, as in other markets.

Latest news

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    two primary endpoints in the MYSTIC trial of Imfinzi plus AZ’s experimental CTLA4 inhibitor tremelimumab in first-line lung cancer treatment. ... Now, the company has added to the options at its disposal as it tries to bring forward combinations of

  • CRUK forges £30m ‘post-Brexit’ R&D alliance CRUK forges £30m ‘post-Brexit’ R&D alliance

    One UK project – called HUNTER - is getting £5m to look into immunotherapies for liver cancer and will be led by Newcastle University. ... in liver cancer and see if immunotherapies can be a treatment option.

  • London cancer hub launched by Cancer Research UK London cancer hub launched by Cancer Research UK

    Specialist centres unite to collaborate on immunotherapies such as CAR-T. An ambitious plan to turn London into a ‘powerhouse’ of cancer research has been launched, backed with £14m ($18m) in ... Francis Crick Institute – bringing together

  • Affimed rockets on $5bn-plus Roche immuno-oncology deal Affimed rockets on $5bn-plus Roche immuno-oncology deal

    Deal is latest in series of big pharma investments in cancer immunotherapies. ... German biotech Affimed saw its share price more than triple yesterday after Roche’s Genentech agreed an alliance to discover new cancer immunotherapies with a

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    including a go-ahead last year in BRAF V600-postitive non-small cell lung cancer (NSCLC). ... talk of using the cancer immunotherapies and small-molecule BRAF/MEK pair in combination.

More from news
Approximately 22 fully matching, plus 75 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies. ... Precision cancer treatment. The shift towards immunotherapies has been accompanied by another key trend – targeting

  • Deal Watch January 2018

    Back in June 2015 Celgene and Juno announced a ten-year collaboration to combine their respective immunology expertise to develop new immunotherapies for cancer and autoimmune diseases based on T cell ... The incoming cash will be used by Immunomedics to

  • Deal Watch November 2015 Deal Watch November 2015

    A package deal covering up to five cancer immunotherapies, the headline value was $1.56bn with an upfront fee of $60m; the subsequent milestone terms per product could reach in excess ... Sanofi will gain access to BioNTech's mRNA formulation technology

  • Pharma deals in June 2015 Pharma deals in June 2015

    Immune modulators in cancer and beyond. Both Juno Therapeutics and Celgene have had a busy month in forming alliances in the immunotherapy area. ... Near the close of the month, Juno and Celgene announced a $1bn, 10-year collaboration to develop novel

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    Phase 3 immuno-oncology treatment for prostate cancer. 975. Intrexon / Merck Serono. ... 825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    Gaweco will lead Apeiron’s immuno-oncology programmes, overseeing the discovery, clinical and medical functions of the company’s new molecular entities pipeline of cancer immunotherapies. ... His outreach into the worldwide pharmaceutical markets

  • Targovax strengthens board of directors Targovax strengthens board of directors

    of our novel and complementary portfolio of cancer immunotherapies.”.

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    He said: “ Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer. ... Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral

  • Merck’s Richard Murray joins Jounce as CEO Merck’s Richard Murray joins Jounce as CEO

    pembrolizumab. This experience will benefit Jounce, a Cambridge, Massachusetts-based company that specialises in cancer immunotherapies. ... The new CEO sees potential in Jounce, however, with the prospect of cancer immunotherapies an appetising one for

  • Bruno Strigini leaves Merck & Co for Novartis Bruno Strigini leaves Merck & Co for Novartis

    These sales made Novartis the third largest pharma company in cancer for the year. ... The area of anti-PD1 cancer immunotherapies looks to be an important one for many companies, with Bristol-Myers Squibb, Roche and AstraZeneca all developing their own

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

    With the promise of using the body’s own immune system to fight cancer,  immunotherapy has received significant interest from the scientific community,  bringing hope to patients across many cancer indications. ... The first generation of agents has

  • Immuno-oncology; bringing patients closer to treatment

    cure; immunotherapies offer positive news for all stakeholders involved in the fight against cancer. ... Immunotherapies can treat head, neck, lung, prostate, renal, multiple myeloma, AML, ALL and kidney cancer.

  • Immunotherapy in oncology

    We are certainly some distance away from the Obama administration’s moon-shot of curing cancer… or are we? ... Three states of interaction exist in immunoediting;. Elimination, in which the immune response eradicates cancer cells.

  • Focus on immunotherapies: special magazine from Blue Latitude Health

    In this supplementary issue, we’re taking a special look at immunotherapies, and more specifically, the growing buzz around “immuno-oncology” therapies. ... What new immunotherapies in oncology mean for cancer patients and the doctors who would

  • Blue Latitude Health

    Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships. ... Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving.

More from PMHub
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics